Josep Mallolas

Summary

Country: Spain

Publications

  1. doi request reprint Pegylated IFN-alpha2b plus ribavirin for treatment-naive patients coinfected with HCV and HIV
    Josep Mallolas
    Servicio de Enfermedades Infecciosas, Hospital Clinic, Barcelona, Spain
    Expert Rev Anti Infect Ther 6:281-9. 2008
  2. doi request reprint [Treatment of hepatitis C virus in HIV-positive patients]
    Josep Mallolas Masferrer
    Servicio de Infecciones, Hospital Clinic IDIBAPS, Barcelona, Espana
    Gastroenterol Hepatol 34:558-67. 2011
  3. doi request reprint Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study
    Josep Mallolas
    Hospital Clinic Universitari IDIBAPS, University of Barcelona, Barcelona, Spain
    J Acquir Immune Defic Syndr 51:29-36. 2009
  4. ncbi request reprint Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients
    J Mallolas
    Infectious Diseases, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    HIV Med 8:131-4. 2007
  5. ncbi request reprint Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study
    J Mallolas
    Hospital Clinic, Barcelona, Spain
    HIV Med 8:226-33. 2007
  6. ncbi request reprint Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adults
    Josep Mallolas
    Infectious Diseases Service, Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    AIDS 22:377-84. 2008
  7. ncbi request reprint A randomized trial comparing the efficacy and tolerability of two HAART strategies at two years in antiretroviral naive patients
    J Mallolas
    Infectious Diseases Service, Hospital Clinic, Barcelona, Spain
    Rev Clin Esp 207:427-32. 2007
  8. ncbi request reprint Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin
    Montserrat Laguno
    Infectious Diseases Service, Hospital Clinic Universitari de Barcelona, Barcelona, Spain
    J Acquir Immune Defic Syndr 44:174-8. 2007
  9. ncbi request reprint Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients
    Montse Laguno
    Infectious Diseases Unit, Hospital Clinic Barcelona, Barcelona, Spain
    Antivir Ther 10:423-9. 2005
  10. doi request reprint Prevalence and clinical relevance of occult hepatitis B in the fibrosis progression and antiviral response to INF therapy in HIV-HCV-coinfected patients
    Montserrat Laguno
    Infectious Diseases Unit, Hospital Clinic, Villarroel, 170, Barcelona, Spain
    AIDS Res Hum Retroviruses 24:547-53. 2008

Detail Information

Publications59

  1. doi request reprint Pegylated IFN-alpha2b plus ribavirin for treatment-naive patients coinfected with HCV and HIV
    Josep Mallolas
    Servicio de Enfermedades Infecciosas, Hospital Clinic, Barcelona, Spain
    Expert Rev Anti Infect Ther 6:281-9. 2008
    ..Although adverse events are extremely common with this combined treatment, it is also true that their handling by experts means that only 10-15% of patients must abandon treatment...
  2. doi request reprint [Treatment of hepatitis C virus in HIV-positive patients]
    Josep Mallolas Masferrer
    Servicio de Infecciones, Hospital Clinic IDIBAPS, Barcelona, Espana
    Gastroenterol Hepatol 34:558-67. 2011
    ....
  3. doi request reprint Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study
    Josep Mallolas
    Hospital Clinic Universitari IDIBAPS, University of Barcelona, Barcelona, Spain
    J Acquir Immune Defic Syndr 51:29-36. 2009
    ..To evaluate the efficacy and safety of switching from boosted lopinavir (LPV/r) to boosted atazanavir (ATV/r) in virologically suppressed HIV-1-infected patients versus continuing LPV/r...
  4. ncbi request reprint Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients
    J Mallolas
    Infectious Diseases, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    HIV Med 8:131-4. 2007
    ..However, administration of rifampicin in combination with antiretroviral therapy, particularly protease inhibitors, is difficult because of drug-drug interactions...
  5. ncbi request reprint Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study
    J Mallolas
    Hospital Clinic, Barcelona, Spain
    HIV Med 8:226-33. 2007
    ..We evaluated the relationship between the saquinavir (SQV) inhibitory quotient (IQ) (virtual and genotypic) and virological response...
  6. ncbi request reprint Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adults
    Josep Mallolas
    Infectious Diseases Service, Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    AIDS 22:377-84. 2008
    ..Induction-maintenance strategies were associated with a low response rate. We compared the virological response with two different induction regimens with trizivir plus efavirenz or lopinavir/ritonavir...
  7. ncbi request reprint A randomized trial comparing the efficacy and tolerability of two HAART strategies at two years in antiretroviral naive patients
    J Mallolas
    Infectious Diseases Service, Hospital Clinic, Barcelona, Spain
    Rev Clin Esp 207:427-32. 2007
    ....
  8. ncbi request reprint Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin
    Montserrat Laguno
    Infectious Diseases Service, Hospital Clinic Universitari de Barcelona, Barcelona, Spain
    J Acquir Immune Defic Syndr 44:174-8. 2007
    ..Few data are available in HIV/HCV-coinfected patients, however...
  9. ncbi request reprint Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients
    Montse Laguno
    Infectious Diseases Unit, Hospital Clinic Barcelona, Barcelona, Spain
    Antivir Ther 10:423-9. 2005
    ....
  10. doi request reprint Prevalence and clinical relevance of occult hepatitis B in the fibrosis progression and antiviral response to INF therapy in HIV-HCV-coinfected patients
    Montserrat Laguno
    Infectious Diseases Unit, Hospital Clinic, Villarroel, 170, Barcelona, Spain
    AIDS Res Hum Retroviruses 24:547-53. 2008
    ..Despite the high prevalence, this phenomenon does not seem to affect the clinical evolution of chronic hepatitis C or modify the viral response to interferon-based HCV therapies..
  11. ncbi request reprint Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor
    Jose L Blanco
    Infectious Diseases Service, IDIBAPS, Hospital Clinic, Faculty of Medicine, University of Barcelona, Barcelona, Spain
    AIDS 19:829-31. 2005
    ..Only one of the 66 patients developed changes in their pattern of mutations able to generate or increase resistance to new drugs...
  12. ncbi request reprint Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction
    Esteban Martinez
    Infectious Diseases Unit, Hospital Clinic Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, C Villarroel 170, 08036 Barcelona, Spain
    AIDS 24:F1-9. 2010
    ..To assess the effects of initiating abacavir-containing therapy on plasma lipids and cardiovascular biomarkers...
  13. doi request reprint Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz T
    Jose M Miro
    Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    AIDS Res Hum Retroviruses 26:747-57. 2010
    ..At 1 and 3 years, the immune reconstitution induced by an efavirenz-based regimen in very immunosuppressed patients was at least as potent as that induced by a ritonavir-boosted protease inhibitor-based antiretroviral regimen...
  14. ncbi request reprint Clinicoimmunological progression and response to treatment of long-term nonprogressor HIV-hepatitis C virus-coinfected patients
    Pedro Castro
    Infectious Diseases Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, University of Barcelona, Spain
    AIDS Res Hum Retroviruses 23:863-7. 2007
    ..HCV-treated LTNP could have a worse HIV progression than HIV-HCV-treated NP or untreated coinfected LTNP. HCV infection does not have a deleterious effect on the progression of LTNP...
  15. ncbi request reprint A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression
    Esteban Martinez
    Hospital Clinic Institut d Investigaciones Biomediques August Pi i Sunyer, University of Barcelona, 08036 Barcelona, Spain
    J Acquir Immune Defic Syndr 51:290-7. 2009
    ..We compared 48-week efficacy and safety of these combinations as substitutes of nucleosides in patients with virological suppression...
  16. pmc Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin
    Natalia Laufer
    Infectious Diseases Unit, Hospital Clinic, Barcelona, Spain
    Antivir Ther 13:953-7. 2008
    ..The aim of our study was to evaluate the effect of ABC on the response rate to HCV therapy...
  17. ncbi request reprint High rate of virological failure in maintenance antiretroviral therapy with didanosine and tenofovir
    Agathe Leon
    Infectious Diseases Unit, Hospital Clinic, University of Barcelona, Spain
    AIDS 19:1695-7. 2005
    ..These results argue against the use of tenofovir-didanosine not only in naive patients, but also in previously suppressed patients...
  18. doi request reprint Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and Darunavir/Ritonavir 800/100 mg once daily in HIV-1-infected patients
    María Martínez-Rebollar
    Infectious Diseases Service, Hospital Clinic, IDIBAPS, Barcelona, Spain
    Ther Drug Monit 35:552-6. 2013
    ..We explore the plasma PK profile of raltegravir (RAL) at a dose of 400 mg twice a day plus darunavir/ritonavir (DRV/RTV) at a dose of 800/100 mg once a day in HIV-1-infected patients...
  19. ncbi request reprint Antiretroviral activity of didanosine in patients with different clusters of reverse transcriptase mutations
    Jose Luis Blanco
    Infectious Diseases Unit, University of Barcelona, Spain
    AIDS 20:1891-2. 2006
    ..0152) or thymidine-associated (P = 0.0142) mutations. In conclusion, ddI retained substantial antiretroviral activity when the number of nucleoside-associated or thymidine-associated mutations was less than four...
  20. ncbi request reprint Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine
    Agathe Leon
    Infectious Diseases Unit, Hospital Clinic, University of Barcelona, Spain
    AIDS 19:213-5. 2005
    ..These results argue against the use of tenofovir plus didanosine in HIV-infected antiretroviral-naive adults even when the third drug is a non-nucleoside reverse transcriptase inhibitor...
  21. doi request reprint Evaluation of the safety and effectiveness of nevirapine plus coformulated tenofovir/emtricitabine as first-line therapy in routine clinical practice
    Gabriel Vallecillo
    Department of Internal Medicine, Hospital del Mar, Barcelona, Spain
    AIDS Res Hum Retroviruses 28:165-70. 2012
    ..03) with an increase in HDL-cholesterol (p=0.01) over 48 weeks. The combination of nevirapine plus cTDF/FTC showed a high virological efficacy without unexpected toxicities as a first-line treatment in a routine clinical practice...
  22. doi request reprint [Current status of acute hepatitis C]
    María Martínez-Rebollar
    Servicio de Infecciones, Hospital Clinic, Barcelona, Espana
    Enferm Infecc Microbiol Clin 29:210-5. 2011
    ..The optimal treatment regimen (interferon alone or combined with ribavirin) and its duration are not clearly established at the present time...
  23. ncbi request reprint Primary human immunodeficiency virus type 1 infection: clinical, virological and immunological characteristics of 75 patients (1997-2003)
    Omar Sued
    Servicios de Enfermedades Infecciosas, Hospital Clinic, Instituto de Investigaciones Biomédicas August Pi i Sunyer IDIBAPS, Universidad de Barcelona, Villaroel 170, 08036 Barcelona, Spain
    Enferm Infecc Microbiol Clin 24:238-44. 2006
    ..To describe the epidemiological and clinical characteristics and the evolution of a cohort of patients with primary HIV-1 infection from the Barcelona area...
  24. ncbi request reprint [Advances in the diagnosis and treatment of hepatitis C virus infection in patients with and without HIV infection]
    Montse Laguno
    Servicio de Enfermedades Infecciosas, Hospital Clínic Universitari de Barcelona IDIBAPS, Universitat de Barcelona, Spain
    Enferm Infecc Microbiol Clin 23:32-40. 2005
    ..Currently, the combination of ribavirine and a new pegilated formulation of the interferon has become the standard in the treatment reaching rates of sustained viral response around 40-80%...
  25. ncbi request reprint Low rate of sustained virological response in an outbreak of acute hepatitis C in HIV-infected patients
    Montserrat Laguno
    Infectious Diseases, University of Barcelona, Spain
    AIDS Res Hum Retroviruses 28:1294-300. 2012
    ..There is a risk of sexual transmission of HCV in HIV-infected men who have sex with men. In our experience, early treatment of AHC with pegylated interferon-alfa plus ribavirin in HIV patients achieves poor results...
  26. ncbi request reprint Noninvasive diagnosis of hepatic fibrosis in HIV/HCV-coinfected patients
    Maria Larrousse
    Infectious Diseases Unit, Hospital Clínic Universitari de Barcelona IDIBAPS, University of Barcelona, Spain
    J Acquir Immune Defic Syndr 46:304-11. 2007
    ..Several serum markers reflecting extracellular matrix status have been correlated with liver fibrosis in non-HIV-infected patients with chronic hepatitis C infection. These indexes have been less examined in HIV/HCV-coinfected individuals...
  27. ncbi request reprint The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients
    Ana Milinkovic
    Infectious Diseases Unit, Hospital Clinic Barcelona, Barcelona, Spain
    Antivir Ther 12:407-15. 2007
    ..We assessed the safety and efficacy of reducing the dose of stavudine compared with switching to tenofovir or maintaining the standard dose of d4T...
  28. ncbi request reprint Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study)
    Esteban Ribera
    Infectious Diseases Service, Hospital Universitari Vall d Hebron, Barcelona, Spain
    J Acquir Immune Defic Syndr 40:317-23. 2005
    ....
  29. doi request reprint Pharmacokinetic study of saquinavir 500 mg plus ritonavir (1000/100 mg twice a day) in HIV-positive pregnant women
    María Martínez-Rebollar
    Infectious Diseases Service, IDIBAPS, Hospital Clinic, Barcelona, Spain
    Ther Drug Monit 33:772-7. 2011
    ..No vertical transmissions were reported. Therapeutic drug monitoring of SQV during pregnancy should be considered, mainly during the third trimester, to ensure adequate drug exposure throughout the entire pregnancy...
  30. ncbi request reprint Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients
    Montserrat Laguno
    Infectious Diseases Unit, the Pathology Service, Hospital Clínic Universitari de Barcelona IDIBAPS, University of Barcelona, Spain
    AIDS 18:F27-36. 2004
    ..We have evaluated the efficacy and safety of interferon alfa-2b (IFN) + ribavirin (RBV) versus pegylated interferon alfa-2b (PEG-INF) + RBV...
  31. ncbi request reprint Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults
    Esteban Martinez
    Infectious Diseases Unit, Hospital Clinic, University of Barcelona, Calle Villarroel 170, 08036 Barcelona, Spain
    Lancet 364:65-7. 2004
    ..666, 95% CI 1.246-91.294, p=0.031). These results suggest that the risk of pancreatitis is heightened when didanosine and tenofovir are given together...
  32. ncbi request reprint Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count
    Felipe Garcia
    Clinic Institute of Infectious Diseases and Immunology, IDIBAPS, Hospital Clinic, Faculty of Medicine, University of Barcelona, Spain
    J Acquir Immune Defic Syndr 36:702-13. 2004
    ..It seems that the immune recovery slows down after approximately 3 years of HAART and reaches a plateau after 4-5 years of HAART...
  33. doi request reprint Restoration of T cell responses to toxoplasma gondii after successful combined antiretroviral therapy in patients with AIDS with previous toxoplasmic encephalitis
    Marylène Lejeune
    Immunology Service, Hospital Clinic Institut d Investigacions Biomèdiques Augustí Pi i Suñer, University of Barcelona, Barcelona, Spain
    Clin Infect Dis 52:662-70. 2011
    ..It is unknown whether a Toxoplasma gondii-specific T cell response is restored after successful combined antiretroviral therapy (cART) in patients with AIDS and current or previous toxoplasmic encephalitis (TE)...
  34. doi request reprint Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study
    Cristina Tural
    HIV Clinical Unit, Internal Medicine Department and Fundació de la Lluita contra la SIDA, University Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain
    Antivir Ther 16:833-41. 2011
    ..It is uncertain whether a 4-week induction period of pegylated interferon and ribavirin increases early virological response (EVR) in HIV-HCV-coinfected patients...
  35. pmc Rate and predictors of non-AIDS events in a cohort of HIV-infected patients with a CD4 T cell count above 500 cells/mm³
    Constanza Lucero
    Hospital Clinic, University of Barcelona, IDIBAPS, Barcelona, Spain
    AIDS Res Hum Retroviruses 29:1161-7. 2013
    ..Reduction of CIR of non-AIDS events after cART initiation depends on nadir CD4 T cell count. Most of the controllers patients had a CIR similar to noncontrollers. These data support the early initiation of cART in HIV-infected patients...
  36. ncbi request reprint Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C
    Montserrat Laguno
    Infectious Diseases Unit, Hospital Clinic Universitari de Barcelona, Barcelona, Spain
    Antivir Ther 9:905-9. 2004
    ..In this study, we evaluated the incidence and management of depressive symptoms during IFN-alpha therapy in HIV-infected patients with CHC...
  37. ncbi request reprint Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load
    Juan A Arnaiz
    Hospital Clinic IDIBAPS, University of Barcelona, Spain
    AIDS 17:831-40. 2003
    ....
  38. doi request reprint Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study
    Polyana Monteiro
    Infectious Diseases Unit, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    J Antimicrob Chemother 69:742-8. 2014
    ..Simple and effective antiretroviral regimens avoiding both drug classes may be needed for selected patients...
  39. ncbi request reprint Factors associated with collagen deposition in lymphoid tissue in long-term treated HIV-infected patients
    Alba Diaz
    Department of Pathology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    AIDS 24:2029-39. 2010
    ..The factors associated with fibrosis in lymphoid tissue in long-term treated HIV-infected patients and their correlation with immune reconstitution were assessed...
  40. ncbi request reprint Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy
    Anna Suy
    Obstetric and Gynecological Service, Hospital Clinic of the Institute of Biomedical Investigations, August Pi i Sunyer Hospital, University of Barcelona, Barcelona, Spain
    AIDS 20:59-66. 2006
    ..Pre-eclampsia and/or fetal death have increased sharply in HIV-infected pregnant women receiving HAART...
  41. ncbi request reprint [Clinical and epidemiological study of a series of HIV-infected patients over 50 years old]
    Esperança Antón
    Servicio de Medicina Interna, Corporacio Parc Tauli, Sabadell, Barcelona, Spain
    Enferm Infecc Microbiol Clin 23:145-8. 2005
    ..The objective of this study is to analyse the epidemiological, clinical and evolution characteristics of a clinical series of HIV-infected patients over 50 years old at the time of diagnosis...
  42. ncbi request reprint Therapeutic drug monitoring and the inhibitory quotient of antiretroviral drugs: can they be applied to the current situation?
    Esteve Ribera
    Servicio de Enfermedades Infecciosas, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Enferm Infecc Microbiol Clin 23:41-67. 2005
    ....
  43. pmc A new multidisciplinary home care telemedicine system to monitor stable chronic human immunodeficiency virus-infected patients: a randomized study
    Agathe Leon
    Infectious Diseases Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    PLoS ONE 6:e14515. 2011
    ..This clinical scenario requires a new approach to simplify follow-up appointments and facilitate access to healthcare professionals...
  44. ncbi request reprint Predictors of tonsillar tissue HIV-1 viral burden at baseline and after 1 year of antiretroviral therapy
    Pilar Navarrete
    Infectious Diseases Unit, Clinic Institute of Infectious Diseases and Immunology, Faculty of Medicine, University of Barcelona, Barcelona, Spain
    Antivir Ther 8:635-7. 2003
    ..No correlation was observed after 1 year of antiretroviral therapy. A protease inhibitor-containing regimen was the best predictor of good tonsillar tissue virological response...
  45. ncbi request reprint Gynecomastia among HIV-infected patients is associated with hypogonadism: a case-control study
    Alejandra Biglia
    Infectious Diseases Unit, Hospital Clinic Institut d Investigaciones Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Clin Infect Dis 39:1514-9. 2004
    ..The prevalence, risk factors, and potential hormonal abnormalities associated with gynecomastia in a cohort of HIV-infected men are poorly understood...
  46. ncbi request reprint [Antiretroviral therapy of HIV infection: duration and reasons for changing the first therapeutic regimen in 518 patients]
    Laura Gratacòs
    Servicio de Farmacia, Hospital Clinic, Universidad de Barcelona, Barcelona, Spain
    Med Clin (Barc) 126:241-5. 2006
    ..The objectives of this study are to determine the median duration of different therapy combinations in naive patients between 1998-2000 and the main reasons for changing or stopping this first antiretroviral therapy (ARVT)...
  47. doi request reprint Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption
    Agathe Leon
    Infectious Diseases Department, Hospital Clinic of Barcelona, Villarroel 170, 08036 Barcelona, Spain
    J Antimicrob Chemother 63:184-8. 2009
    ..CD4+ T cell recovery dynamics were analysed during the 'on treatment' periods in structured therapy interruption (STI) as well as the long-term immune reconstitution with highly active antiretroviral therapy (HAART) after finishing STI...
  48. doi request reprint MRI signal changes of the bone marrow in HIV-infected patients with lipodystrophy: correlation with clinical parameters
    Ana I Garcia
    Department of Radiology, Hospital Clinic, Villarroel 170, Barcelona 08036, Spain
    Skeletal Radiol 40:1295-301. 2011
    ..To assess the prevalence, imaging appearance, and clinical significance, of bone marrow MR signal changes in a group of human immunodeficiency virus (HIV)-infected patients with lipodystrophy syndrome...
  49. ncbi request reprint [Spanish recommendations for proper use of enfuvirtide]
    Esteban Ribera
    Hospital Vall d Hebron, Barcelona, Espana
    Enferm Infecc Microbiol Clin 25:131-42. 2007
    ....
  50. ncbi request reprint Metabolic and immunological effects of antiretroviral agents in healthy individuals receiving post-exposure prophylaxis
    Felipe Garcia
    Infectious Diseases Unit, University of Barcelona, Barcelona, Spain
    Antivir Ther 7:195-7. 2002
    ..This antiretroviral regimen seems to have no effect on lymphocyte T cell subsets, however, it could have an immune-modulator role, inducing an increase in the proliferative responses to mitogens...
  51. ncbi request reprint Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir versus continued HAART: the Trizal study
    Alain Lafeuillade
    Department of Infectious Diseases, Chalucet Hospital, Toulon, France
    HIV Clin Trials 4:37-43. 2003
    ..To analyze the evolution of clinical lipodystrophy (LD) and metabolic abnormalities in patients continuing to receive HAART versus patients switched to Trizivir (zidovudine, lamivudine, abacavir) after 48 weeks...
  52. ncbi request reprint Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine
    Ulrich A Walker
    Medizinische Universitatsklinik, Department of Clinical Immunology, Freiburg, Germany
    Hepatology 39:311-7. 2004
    ..Moderate mtDNA depletion in liver does not necessarily lead to hyperlactatemia, but more pronounced decreases in hepatic mtDNA may be an important contributor to lactate elevation...
  53. ncbi request reprint Prevention of opportunistic infections in adult and adolescent patients with HIV infection. GESIDA/National AIDS Plan guidelines, 2004 [correction]
    Juan Berenguer
    Unidad de Enfermedades Infecciosas, Hospital General Gregorio Maranon, Madrid, Spain
    Enferm Infecc Microbiol Clin 22:160-76. 2004
    ..To provide an update of guidelines from the Spanish AIDS Study Group (GESIDA) and the National AIDS Plan (PNS) committee on the prevention of opportunistic infections in adult and adolescent HIV-infected patients...
  54. ncbi request reprint [Comparison of three methods to calculate adherence in patients receiving antiretroviral treatment]
    Carlos Codina
    Servicio de Farmacia Hospital Clinic de Barcelona Spain
    Enferm Infecc Microbiol Clin 20:484-90. 2002
    ..The aim of this study was to compare three of the available methods for assessing medication adherence in order to determine their accuracy for this purpose...
  55. ncbi request reprint Hepatic steatosis with stavudine in HIV/hepatitis C virus co-infection
    Jochen Bäuerle
    AIDS 19:1441-2. 2005
  56. ncbi request reprint Nevirapine-associated hepatotoxicity in virologically suppressed patients--role of gender and CD4+ cell counts
    Josep Mallolas
    AIDS Rev 8:238-9. 2006
  57. ncbi request reprint Transmission of HIV-1 from an obstetrician to a patient during a caesarean section
    Josep Mallolas
    Infectious Diseases and Microbiology Services, Spain
    AIDS 20:285-7. 2006
    ..8-3.1). HIV can be transmitted from an infected HCW to a patient when percutaneous injuries with subsequent exposure of the patient to the blood of the HCW can occur...
  58. ncbi request reprint Transmission of HIV-1 from an obstetrician to a patient during a caesarean section
    Josep Mallolas
    AIDS 20:1785. 2006